March 16 - Human Genome Sciences Inc. Said It Will Develop and commercialization Privately Held a biotech firm's drug for multiple cancers In The United States, Canada and European Markets.
Under the deal, FivePrime Therapeutics Inc. Will Get an upfront license payment of $ 50 million and Will Be Eligible to Receive up to $ 445 million in milestone payments, Along With double-digit royalty payments on net Percentage dirty.
FivePrime Will retain co-promotion Minority Rights in the United States and full development and commercialization rights in The Rest of World, Including Asia, The Companies Said in a statement http://psychologydegree-online.com/somatic-psychology-programs/.
The drug, FP-1039, targets multiple fibroblast growth factor ligands. It is currently in mid-stage trials for a form of endometrial cancer.
The company's shares closed Wednesday at $ 27.41 it is Nasdaq.
(Reporting by Shravya Jain, Editing by Maju Samuel)
Recent Comments